SI-BONE (SIBN) Q3 2026 earnings review
SI-BONE surgeries speed up, but cheaper procedures hold back sales
SI-BONE, a maker of implants for weak spinal and pelvic bone, grew U.S. surgeries faster than its doctor base while lower prices held back revenue. Third-quarter sales rose 14% from a year ago to $56 million as outpatient clinics used cheaper implants, and tighter overhead cut the operating loss. Chief executive Laura Francis kept the full-year sales plan unchanged, which by our math leaves revenue growth stepping up to 20% in the fourth quarter.
| Worldwide revenue | $55.7M +14.5% from a year ago |
|---|---|
| U.S. procedure volume growth | +19.5% +15.7% active U.S. physician growth |
| Full-year revenue outlook | Unchanged $231–233M (leaves ~20% growth for Q4) |
| Full-year operating expense outlook | Cut to +10.5% prior plan: +12.0% growth |
⚖️ Verdict: 🟢 Bullish
The story got better because doctors performed more surgeries each for the first time in over a year, and both fourth-quarter catalysts arrived on time. The company won FDA clearance for its Onyx spinal implant in September, Medicare's higher hospital payments took effect in October, and slower spending allowed a cut to the full-year cost plan. One caution: capital spending on surgical trays jumped to $6 million by our math and wiped out free cash flow.
The question now is whether the unchanged full-year sales outlook is simple caution or a sign that outpatient price pressure is offsetting the new hospital launches. If hospital adoption of Bedrock Granite and Onyx is strong, fourth-quarter sales will beat the $68 million implied target; if clinics dominate, lower average prices will cap growth. Fourth-quarter U.S. revenue growth against procedure volume will settle it.
🐂 Bull Case
Procedures Per Doctor Rose Again
SI-BONE tracks how many U.S. doctors perform at least one surgery with its bone implants each quarter. For over a year, that doctor count grew 3 to 9 percentage points faster than total U.S. surgeries, because newly trained doctors perform fewer procedures than experienced ones. That gap reversed in the third quarter.
- U.S. procedure volume growth: 19.5% from a year ago, up from 14.9% in the second quarter
- Active U.S. physicians: 1,770, up 15.7% from a year ago (55 added since last quarter)
- Output per active physician: up about 3% from a year ago by our math
This reversal matters because the full-year revenue plan requires doctors to do more surgeries each, not just for the sales team to sign up new doctors. One quarter narrows the concern rather than settling it, because a record 330 doctor additions a year ago made the physician comparison unusually tough.
What to watch: U.S. procedure growth against active doctor growth in the fourth quarter. A second quarter where surgery growth outpaces doctor additions would confirm that multi-product adoption is lifting output per doctor.
FDA Cleared Onyx Ahead of Schedule
SI-BONE makes implants that anchor the base of the spine to the pelvis, and it has been preparing two fourth-quarter catalysts to expand beyond its original joint-fusion business. Both arrived on or ahead of schedule. In September, the Food and Drug Administration cleared iFuse Granite Onyx, a new implant system "targeting failures in spine fusion procedures, with an estimated total addressable market of ~$1.5 billion annually".
In October, "new MS-DRGs took effect for complex spinal fusion procedures incorporating iFuse Bedrock Granite, increasing average hospital inpatient payments by up to ~$50,000 per qualifying procedure". Higher Medicare hospital payments remove the cost barrier for hospitals using the Bedrock Granite spinal anchor, while the Onyx clearance lets surgeons use SI-BONE's implants higher up the spine.
What to watch: fourth-quarter U.S. revenue and procedure volume in the full-year report. A jump in U.S. revenue growth toward 20% would show that higher Medicare payments and Onyx are converting into hospital orders.
Slower Overhead Growth Cut the Loss
SI-BONE is still unprofitable on a standard accounting basis, but it is narrowing the gap by holding down administrative costs while sales grow. Operating loss shrank 19.2% from a year ago to $4.4 million, and operating margin improved by 3.3 percentage points to negative 7.8%.
General and administrative overhead did the work, falling 2.5 percentage points of revenue to 18.1%. Sales and marketing costs (commissions and launch marketing) fell 0.8 percentage points to 60.8% of revenue, and research and development fell 0.5 percentage points to 8.2%. Because spending stayed controlled through September, the medical-device maker cut its full-year operating expense growth plan from 12.0% to 10.5%.
What to watch: fourth-quarter operating expenses, which the updated outlook still puts at about 20% growth from a year ago by our math. Coming in below that rate would bring standard accounting breakeven closer in 2027.
🐻 Bear Case
Outpatient Mix Pushed Prices Down
While doctors performed 19.5% more U.S. surgeries with SI-BONE's devices than a year ago, U.S. revenue rose only 13.9% to $52.8 million. By our math, the average revenue per U.S. procedure fell about 4.7% from a year ago, a wider gap than in the second quarter, when procedures grew 14.9% and U.S. revenue rose 14.7%.
SI-BONE attributed the gap to "lower average selling price due to procedure mix and the growing interventional spine physician demand for the INTRA platform in the office-based and ASC sites of care". INTRA is a smaller implant system used by pain specialists in outpatient clinics rather than hospital operating rooms, and those cases use cheaper or fewer implants. That mix shift also pushed gross margin down 0.5 percentage points to 79.3%.
What to watch: the gap between U.S. procedure growth and U.S. revenue growth in the fourth quarter. As hospital spinal-fusion cases using Bedrock Granite and Onyx ramp up, average price per procedure should stop falling.
Unchanged Plan Still Needs a Big Fourth Quarter
Chief executive Laura Francis pointed to "exceptional early uptake in our alpha launch of iFuse Granite Onyx", and third-quarter revenue of $55.7 million beat the $54.9 million to $55.5 million range that management's prior commentary pointed to by our math. Even so, SI-BONE left its full-year revenue outlook unchanged at $231 million to $233 million, ending a streak of six straight quarterly raises across 2025 and 2026.
Beating the third-quarter seasonal dip while leaving the full year flat means the company did not bank the beat. By our math, hitting the $232 million middle of the full-year range still requires fourth-quarter revenue of $67.7 million, or 20.1% growth from a year ago, up from 14.5% growth in the third quarter.
What to watch: whether fourth-quarter revenue clears the $66.7 million to $68.7 million range implied by the full-year outlook. Anything below 18% growth would mean the new hospital reimbursement and Onyx launch ramped more slowly than planned.
New Surgical Trays Consumed the Cash
SI-BONE highlighted $5.9 million of positive cash from operations in the third quarter, up 154% from a year ago. However, launching new implant systems requires buying surgical instrument sets to place in hospitals and building implant stock before sales happen, which the release notes as "future capital requirements driven by new surgical systems requiring instrument tray and implant inventory investment".
- Third-quarter capital spending: $6.4 million by our math (11.4% of revenue), up from $2.6 million in the entire first half
- Third-quarter free cash flow: negative $0.4 million by our math, bringing the nine-month cash burn to $4.6 million
- Inventory on the balance sheet: $42.4 million, up 25.0% since December against 13.6% nine-month revenue growth
What to watch: fourth-quarter purchases of property and equipment and inventory levels. Once the initial Onyx instrument trays are built, capital spending needs to drop back so operating cash flow turns into free cash flow.
Risks this quarter didn't answer
Four standing items from prior quarters were not disclosed in the third-quarter earnings release and await the conference call or the quarterly 10-Q filing.
- Sales territory managers: not in the release after reaching 93 in the second quarter; the call remarks will show progress toward the year-end target of nearly 100.
- Revenue per territory: omitted from the release after growth slowed to 5% in the second quarter; any update on the call will show whether new hires are diluting output.
- Department of Justice investigation: the October 2024 civil investigative demand into physician meals and consulting payments gets its quarterly status check in the 10-Q legal footnote.
- Smith + Nephew trauma partnership: no revenue figure or training completion date was given in the release.
💲 Other KPIs
International sales rose 27.0% from a year ago to $2.9 million, edging up from 25.9% growth in the second quarter. SI-BONE said growth came from European and Australian adoption of iFuse TORQ and iFuse TORQ TNT, its threaded bone implants, though overseas markets still represent just 5.2% of total sales.
Weighted-average shares rose 4.0% from a year ago to 44.9 million, matching the 3.9% dilution pace of the first half. The surgical-implant maker does not buy back shares and paid $5.7 million in employee stock compensation during the quarter, which was nearly double its $3.0 million of adjusted EBITDA.
Total cash and marketable securities rose by $0.4 million from June to $146.3 million, compared with $35.7 million of long-term debt. Higher accounts payable helped operating cash flow cover the third-quarter surge in surgical tray purchases without drawing down the cash reserve.
🔮 Guidance
Unchanged. The plan still calls for 15% to 16% annual growth, or 15.5% at the $232 million middle of the range. By our math, that leaves $67.7 million for the fourth quarter, or 20.1% growth from a year ago versus 14.5% in the third quarter. After raising the outlook in the first two quarters (+$1.0M, +$0.5M), the company held it flat this time.
Unchanged. SI-BONE kept its full-year gross margin target at 79.0% after reporting 79.5% across the first nine months. By our math, that leaves about 77.7% for the fourth quarter, down from 79.3% in the third quarter, as depreciation on new Onyx surgical trays and outpatient procedure mix weigh on unit margins.
Improved. Management lowered its expected full-year operating expense growth by 1.5 percentage points to 10.5%, following a 0.5-point cut last quarter. Because operating expenses grew only 7.2% across the first nine months, the 10.5% full-year figure still leaves about 20.1% expense growth for the fourth quarter by our math as launch marketing ramps up.
Unchanged. The spinal-implant maker still expects positive full-year adjusted EBITDA, which is profit before interest, taxes, depreciation and employee stock awards. With $8.4 million already generated in the first nine months (including $3.0 million in the third quarter), the company has cleared this floor with a wide cushion.
❓ Key Questions
Why did SI-BONE hold the revenue outlook after beating Q3?
Third-quarter revenue beat the seasonal dip management had pointed to, and the Onyx implant cleared the FDA in September. Holding the full-year range flat suggests either fourth-quarter hospital orders are starting slowly or outpatient price pressure is offsetting higher volume.
How much more capital will Onyx surgical trays require?
By our math, property and equipment purchases jumped to $6.4 million in the third quarter from $2.6 million in the entire first half. Investors need to know whether the initial hospital tray build is finished or will keep free cash flow negative in 2027.
Did revenue per sales territory slow further in Q3?
Trailing 12-month revenue growth per territory slowed from 23% a year ago to 5% in the second quarter, and the third-quarter release omitted both territory count and productivity. Those numbers show how fast new sales reps are ramping.
What is the status of the Department of Justice inquiry?
SI-BONE received a civil investigative demand in October 2024 regarding doctor meals and consulting payments and has recorded no legal reserve. Any settlement or limits on doctor training events could slow physician recruiting.